Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $2.4 million.

  • Protalix BioTherapeutics' Income from Continuing Operations fell 2540.17% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 15676.66%. This contributed to the annual value of $2.9 million for FY2024, which is 4383.14% down from last year.
  • Protalix BioTherapeutics' Income from Continuing Operations amounted to $2.4 million in Q3 2025, which was down 2540.17% from $164000.0 recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Income from Continuing Operations high stood at $16.2 million for Q2 2023, and its period low was -$11.4 million during Q2 2021.
  • Its 5-year average for Income from Continuing Operations is -$1.9 million, with a median of -$3.2 million in 2022.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Income from Continuing Operations crashed by 217987.42% in 2021, and later surged by 40388.08% in 2023.
  • Protalix BioTherapeutics' Income from Continuing Operations (Quarter) stood at -$6.6 million in 2021, then soared by 51.47% to -$3.2 million in 2022, then crashed by 88.29% to -$6.0 million in 2023, then surged by 207.45% to $6.5 million in 2024, then plummeted by 62.83% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $164000.0 for Q2 2025, and -$3.6 million during Q1 2025.